Evolving Role and Clinical Evidence in the Global Practice of Balloon Pulmonary Angioplasty

Balloon pulmonary angioplasty (BPA) was first described in 2001 and now has evolved into a class I indication for inoperable or residual chronic thromboembolic pulmonary hypertension. This review article aims to describe evidence from studies performed at various pulmonary hypertension (PH) centers...

Full description

Saved in:
Bibliographic Details
Published inInterventional cardiology clinics Vol. 12; no. 3; p. 417
Main Authors Jain, Nishant, Perkins, Sidney, Maligireddy, Anand Reddy, Rosenfield, Kenneth
Format Journal Article
LanguageEnglish
Published Netherlands 01.07.2023
Subjects
Chronic thromboembolic pulmonary hypertension
Pulmonary endarterectomy
Chronic thromboembolic pulmonary disease
Balloon pulmonary angioplasty
Pulmonary hypertension
Online AccessGet more information

Cover

More Information
Summary:Balloon pulmonary angioplasty (BPA) was first described in 2001 and now has evolved into a class I indication for inoperable or residual chronic thromboembolic pulmonary hypertension. This review article aims to describe evidence from studies performed at various pulmonary hypertension (PH) centers across the globe, to better understand the role of BPA in chronic thromboembolic pulmonary disease with and without PH. Additionally, we hope to highlight innovations and the ever-changing safety and efficacy profile of BPA.
ISSN:2211-7466
DOI:10.1016/j.iccl.2023.03.008